Articles tagged with Cancer Medication
Researchers discovered that FAIM can affect cancer cell proliferation and silencing its expression destroys myeloma cells. Higher levels of FAIM correlate with poorer survival outcomes, making it a useful biomarker for multiple myeloma patients.
Researchers identified a previously unidentified virus in raccoons that may be contributing to the development of brain tumors. The study found that this virus, dubbed raccoon polyomavirus, is present in all affected animals and may play a role in tumor formation.
Recent advancements in lung cancer treatment focus on targeting specific genetic mutations, resulting in improved patient response rates (70-80%) compared to traditional chemotherapies. However, challenges remain in securing funding for clinical trials and staying ahead of the disease's rapid mutation rate.
Consumers believe that life-saving products like vaccines and cancer medications are priced based on need rather than profit. This perception can lead to an increased perceived health risk when prices are low, even if the product is still necessary.
A new study reveals that the SIRT6 gene plays a critical role in suppressing cancer growth by repressing aerobic glycolysis and inhibiting Myc activity. The loss of SIRT6 protein in mice increases tumor size and aggressiveness, highlighting its potential as a tumor suppressor.
Researchers have genetically engineered algae to produce a complex and expensive human therapeutic drug used to treat cancer. The method could be used to make novel complex designer drugs that can't be produced in any other systems, potentially driving down prices dramatically.
Boston College researcher Marc-Jan Gubbels is working on new drugs to prevent toxoplasmosis in cancer patients with weakened immune systems. The goal is to trap the parasite within cells and prevent it from attacking, which could lead to the development of more effective treatments with fewer side effects.
A new class of drugs has been shown to reduce the risk of graft-vs.-host disease, a deadly side effect of lifesaving bone marrow transplants, by half. The study used vorinostat, a cancer drug with anti-inflammatory effects, and found it safe and tolerable for patients undergoing reduced-intensity bone marrow transplants.
A Phase II clinical trial found that over a third of high-risk leukemia patients responded to the experimental new drug quizartinib, experiencing complete remission and potentially life-saving bone marrow transplants. Many participants who did well with the drug had failed to respond to prior therapies.
Researchers block DNA repair pathway in leukemia stem cells by targeting protein RAD52, which is crucial for fixing genetic mistakes. This approach may lead to a new strategy to overcome drug resistance in cancer patients.
Scientists discovered blocking a specific protein makes tumors more vulnerable to treatment in mice, hinting at potential new therapies for humans. Researchers are now exploring inhibitors of the protein, which could boost cancer drugs' effectiveness.
Researchers found that Mesupron combined with Capecitabine significantly extended progression-free survival for patients with metastatic breast cancer to 8.3 months, nearly twice that of those taking Capecitabine alone. The study also showed improved results in previously treated patients.
A phase III clinical trial compared eribulin mesylate to capecitabine in women with previously treated metastatic breast cancer, showing a trend towards improved overall survival. The median overall survival was 15.9 months for eribulin and 14.5 months for capecitabine.
Researchers found that some women with HER2 negative breast cancer may still benefit from anti-HER2 drugs due to undetected mutations. The study identified 25 patients with HER2 mutations without amplification, and most responded well to treatment. A phase II clinical trial is now underway to test the effectiveness of these treatments.
A groundbreaking clinical trial reveals that women with estrogen receptor-positive breast cancer who take tamoxifen for 10 years have a lower risk of recurrence and mortality rate compared to those taking the drug for 5 years. This new finding may prompt patients to reconsider their treatment options, particularly premenopausal women.
The study, led by Peter Jones, identified specific genes that must be turned off for cancer cells to survive. The findings provide a new target for cancer treatments and may lead to more effective medicine.
Research by Nemours and University of Delaware teams found improved quality of life and survival in leukemia patients treated with nanoparticle-based drug delivery. The approach reduces side effects and allows precise targeting of cancer cells, offering a promising alternative to traditional chemotherapy.
A new drug demonstrated dramatic effects on prostate cancer that had spread to the bone, with two-thirds of patients showing improvements on their bone scans. Additionally, 67% of patients with bone pain reported improved pain control after treatment with cabozantinib.
The growing US population and increased life expectancy necessitate new approaches to prostate cancer treatment. Researchers are exploring targeted therapies, immunotherapy, and precision radiation targeting to improve treatment outcomes for older patients.
A Mayo Clinic-led study found that patients with ovarian cancer who took metformin for their diabetes had a better survival rate than those who did not take the medication. After five years, 67% of metformin-takers were still alive compared to 47% of non-takers.
Researchers found that ovarian cancer patients who took metformin lived significantly longer than those who did not, with a 3.7 times increased survival rate after accounting for other factors. The study suggests metformin may be considered for prevention or treatment of ovarian cancer.
The American Society of Clinical Oncology (ASCO) has released its annual report on the top cancer advances of 2012, showcasing significant developments in precision medicine and targeted treatments. The report highlights seven new FDA approvals for anticancer agents, including therapies for breast and prostate cancers.
Researchers identified a transporter molecule on the surface of cancer cells that can take in a toxic substance, allowing it to kill cancer cells. This discovery could lead to more targeted and effective cancer treatments.
Researchers have found that targeting resistant lung cancer 'pockets' with focused radiation can prolong disease control in patients who initially respond to crizotinib or erlotinib. This approach showed significant benefits in patients whose cancers progressed in the brain, where the drugs are less effective.
Researchers have discovered how two proteins regulate telomeres, the protective caps on chromosome ends. The POT-1/TTP-1 complex promotes telomerase activity, a key target for anti-cancer drugs.
A phase I clinical trial has shown that ponatinib is highly active against patients with chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic lymphoma who have developed resistance to standard treatments. The study's findings suggest that ponatinib will expand the therapeutic armamentarium for these patients.
Researchers at UNC and Harvard have discovered a new alternative mechanism for activating the Ras protein, which plays a crucial role in cellular growth control. The discovery, published in Nature Structural and Molecular Biology, shows that modification of Ras with ubiquitin can activate it, leading to cancer formation.
Researchers at Huntsman Cancer Institute have discovered a new drug with high potential to treat Ewing sarcoma by targeting the EWS/FLI protein. The study found that an enzyme called lysine specific demethylase (LSD-1) interacts with EWS/FLI to turn off gene expression in Ewing sarcoma.
Scientists at Karolinska Institutet have found that IGF-1 blockers are only partially effective because they stimulate the MEK channel, allowing cancer cells to survive. Researchers propose a combination therapy using MEK inhibitors and IGF-1 blockers to overcome this issue
Researchers have identified telomerase as a cause of chronic inflammation in human cancers, a key underlying factor for many diseases. Developing drugs to target this enzyme may lead to novel treatments that alleviate common ailments such as cancer and diabetes.
A new targeted drug, regorafenib, has demonstrated its ability to control metastatic gastrointestinal stromal tumor (GIST) in patients who have become resistant to all existing therapies. The treatment improved disease control and survival rates for nearly four months longer than placebo.
A study identified a biomarker that can predict responses to cancer drugs and offers a way to treat drug-resistant tumors. The researchers discovered that inhibition of MED12, a gene mutated in cancers, causes drug resistance by enhancing signaling through the TGF-beta receptor.
Researchers have identified an enzyme used in nature to produce powerful chemicals from catnip, which could be used to create a more affordable and effective cancer treatment. The discovery also has potential applications in agriculture, as the enzyme's product can disrupt aphid breeding cycles or repel them from crops.
Regorafenib has shown significant promise in treating bowel cancer and gastrointestinal stromal tumors (GISTs) after standard treatments fail. Patients receiving regorafenib experienced improved overall survival rates and delayed progression compared to placebo.
Researchers at the University of New South Wales have developed a non-toxic nanoparticle that can deliver nitric oxide to specific cancer cells, reducing chemotherapy doses by a factor of five. This could lead to improved treatment outcomes and reduced side effects for neuroblastoma patients.
A UAlberta researcher has developed 'homing beacon drugs' that selectively kill cancer cells while sparing healthy ones. These smart drugs use nano-technology to identify cancer cells based on a unique protein found only in them, allowing for targeted treatment and potential reduction in side effects.
A phase 3 study published in the New England Journal of Medicine suggests there are benefits to both blood and marrow stem cell transplants, but no significant survival differences were found. Researchers from John Theurer Cancer Center played a key role in this groundbreaking study.
Researchers found that local ablative therapy and continuation of targeted drugs can prolong disease control by up to 6.2 months in patients with EGFR mutations or ALK rearrangements. The study's findings suggest a new approach to treating NSCLC after progression, particularly for patients with oligoprogressive disease.
Scientists at the University of Nottingham have discovered that cordycepin, a compound found in rare parasitic fungi, has potential as an anti-inflammatory drug. The study shows that cordycepin reduces inflammatory gene products in airway smooth muscle cells, making it a potential treatment for asthma and other inflammatory conditions.
Researchers identified PUMA, NOXA, and TRB3 as executors of glutamine-starved cells in Myc-mutant cells. The team showed that drugs targeting these proteins induced cell death in assays using neuroblastoma cells and inhibited tumor growth in transgenic mice.
Researchers found that inhibiting PI3-kinase can convert BRCA-proficient triple-negative breast cancers into BRCA-deficient ones, making them sensitive to PARP inhibitors. This combination treatment showed promising results in preclinical studies and is now being tested in a clinical trial.
Researchers identified 70 genetic mutations in Burkitt lymphoma tumors, including a new mutation that accelerates tumor growth. The findings could lead to the development of new treatments or targeted therapies for cancer patients.
Researchers have identified a specific cellular mechanism that may help overcome endocrine therapy-resistance in patients with estrogen-positive breast cancers. A novel molecular 'crosstalk' point between estrogen and HER2 signaling pathways has been found to drive tamoxifen resistance, according to new findings.
A combination of an anti-HER2 drug and an angiogenesis inhibitor significantly improves survival in a mouse model of brain metastatic breast cancer. The treatment extends patient survival by slowing the growth of brain tumors, making it a promising approach for patients with HER2-positive breast cancer who develop brain metastases.
Rice University chemist Zachary Ball and collaborators aim to create a drug that's effective against an 'undruggable' protein by using metal-based pins. They're attempting to answer whether new technologies can inhibit traditionally undruggable target molecules, including transcription factors required for cancer.
A study by University of Texas M.D. Anderson Cancer Center reveals that doxorubicin's cardiotoxicity is linked to the Top2b enzyme, which drives DNA damage and affects heart muscle metabolism. The discovery could lead to a simple blood test to predict sensitivity to the drug.
Researchers at UC Davis have developed a novel drug delivery system using nanoparticles that targets bladder cancer cells, allowing for higher doses of chemotherapy while reducing side effects. The system also enables diagnostic imaging, offering potential benefits for advanced bladder cancer treatment and management.
A comprehensive review of herbal and dietary supplement interactions reveals potentially harmful drug combinations, particularly among those with central nervous or cardiovascular systems. The study emphasizes the need for increased awareness and monitoring to mitigate risks.
Researchers at CU-Boulder have discovered a novel target for anti-cancer drug development by targeting the telomerase enzyme at the ends of chromosomes. This approach may provide an effective solution to the complex problem of cancerous cells. By blocking the telomerase enzyme, the growth of cancerous cells can be prevented.
Researchers found that Avastin increases survival in around 10-15% of bowel cancer patients by targeting the growth-promoting VEGF165 protein. Patients with lower levels of VEGF165b benefited from the treatment, while those with higher levels saw no improvement.
A study on histone modification could lead to targeted drugs for cancer treatment. Dr. Osley's research focuses on how ubiquitin attaches to H2B and its impact on DNA copying, potentially targeting quiescent cancer cells.
Researchers at Penn are developing programs to help people change high-risk behaviors, such as smoking and overeating, by enhancing the brain's cognitive control system. The study aims to assess the effects of neurocognitive training on decision-making processes and their impact on cancer risk.
Researchers found a daily multivitamin reduced the risk of total cancer by 8% in men over 50. The study also showed an apparent reduction in cancer deaths among those taking a multivitamin.
Researchers at Duke University Medical Center have identified new subtypes of gastric cancer linked to environmental factors. The study's findings suggest that these subtypes may be targeted with specific therapies, improving treatment outcomes for the second leading cancer killer worldwide.
A recent study found that nearly 4 out of 10 lesbians are not routinely screened for cervical cancer, highlighting the need for effective communication with healthcare providers. The study suggests that open communication between patients and providers can significantly increase screening rates among this population.
Researchers at the University of Minnesota have developed a new drug called Minnelide to target and destroy tumor cells in pancreatic cancer. The drug works by inhibiting heat shock protein HSP 70, which aids tumor cell growth, effectively disintegrating the cancer.
Researchers at Dana-Farber Cancer Institute have successfully shut down breast cancer and leukemia in mice by targeting abnormal proteins that control cell growth. The study found that inhibiting cyclin D1 or D3 proteins halts cancer growth, while normal cells remain unaffected.
Researchers have discovered that anti-cancer drugs can induce the growth and repair of muscle tissue by activating a specific cell-signalling pathway. This process involves the fusion of muscle cells to create new muscle fibres or repair damaged fibres.
Scientists at UC Santa Barbara aim to create a synthetic patch of fresh cells to replace malfunctioning ones in the eyes, treating age-related macular degeneration. The Garland Initiative, funded by philanthropist Bill Bowes, will advance regenerative bioengineering and cellular therapies for diabetic retinopathy.
Researchers have identified a novel signalling pathway controlling cellular energy metabolism, independent of the known hedgehog pathway. This discovery suggests that substances targeting this pathway could provide an easy and safe adjunct therapy for diabetes and obesity, resolving complications induced by cancer treatments.